Current difficulties and recent advances in bypass therapy for the management of hemophilia with inhibitors: a new and practical formulation of recombinant factor VIIa

Linda Butros  
Koh Boayue  
Prasad Mathew  
The University of New Mexico, Albuquerque, New Mexico, USA

Abstract: Bypassing agents are the mainstay of treatment for patients with hemophilia with high-titer inhibitors. Whereas the availability of these agents has greatly advanced the management of bleeding episodes in this population, timely administration of bypassing agents continues to be hampered by a number of practical limitations, including the need for refrigerated storage of the agent and its reconstitution at room temperature prior to administration, among others. In this review, the importance of early treatment of bleeds and factors that influence this more timely therapeutic approach are highlighted, together with the advantages offered by the use of a new formulation of recombinant activated factor VII that permits improved storage and portability, potentially optimizing timely bypassing agent administration.

Keywords: hemophilia, inhibitors, bleeding, treatment, patients, recombinant factor VIIa

Introduction

The development of neutralizing alloantibodies (“inhibitors”) to factor VIII or factor IX complicates treatment in 20% to 30% of patients with hemophilia A and 3% to 5% of patients with hemophilia B.1 These inhibitors (polyclonal immunoglobulin G antibodies) also affect any residual endogenous factor that the patient may have and make administration of a replacement factor ineffective, secondary to its rapid clearance from the circulation.2,3 Treatment options, potential complications, and cost of treatment are markedly different for hemophilia patients with inhibitors than for hemophilia patients without inhibitors.1 Since patients with inhibitors no longer achieve adequate hemostasis with factor VIII or factor IX infusions, alternative treatments are required to reduce/eradicate inhibitor titers (eg, immune tolerance induction therapy) or induce coagulation via another pathway in the clotting cascade (ie, bypass therapy).

In this paper, we discuss the importance of early treatment of acute bleeds in patients with inhibitors, which offers a significant therapeutic advantage for minimizing re-bleeds, improves patient quality of life, and reduces consumption of bypassing agent.4 Early treatment can best be achieved by timely administration of bypassing therapy, which is dependent upon drug-related factors or properties that can either inhibit or facilitate this therapeutic goal in patients with inhibitors. Addressing this key point, we also detail the attributes of a new room temperature stable recombinant activated factor VII (rFVIIa) formulation that improves portability and convenience of administration, thereby increasing the likelihood of early and successful treatment of acute bleeding episodes in this patient population.
Importance of early treatment of acute bleeding episodes in inhibitor patients

Available data suggest that early intervention improves treatment efficacy.4,5 Review of data from clinical trials and from studies of the compassionate use of rFVIIa have demonstrated a clear relationship between early treatment and achievement of excellent or effective treatment response, with 92% of patients achieving this endpoint when rFVIIa was initiated within a mean of 1.2 hours of the onset of bleeding versus only 63.1% when rFVIIa was given within a mean of 5 days after bleeding onset.6 Similarly, data from a prospective, observational registry comprising 128 bleeding episodes in 15 patients with inhibitors demonstrated numerically lower rebleeding rates among patients treated with rFVIIa within 2 hours (5.2%) versus patients treated more than 2 hours after the first bleeding symptoms appeared (13.7%).4 By minimizing the extent of bleeding in the joint, prompt treatment may also delay the development of hemophilic arthropathy.6

The improved efficacy of early treatment may also result in reduced bypassing agent consumption by patients. In the study by Lusher, the mean number of doses was lower among patients treated within a mean time interval of 1.2 hours (2.3 doses) than among patients treated within a mean time interval of 5 days (13.6 doses).5

Despite these findings showing the significant therapeutic benefit of early treatment of acute bleeds, timely management is not common among hemophilic youths in the United States. In a survey of 100 hemophilia patients aged 13 to 21 years, only 31% of respondents reported the administration of self-treatment within 1 hour of the onset of a bleeding episode.7 One of the most common reasons cited for treatment delay was the failure to have clotting factor with them at the time of the bleeding episode (25% of respondents).7

Bypassing therapy for patients with inhibitors

Acute bleeding or perioperative bleeding management

Historically, porcine factor VIII (pFVIII) has been used as an alternative to human-derived concentrates in patients with an inhibitor to factor VIII.8 pFVIII has been observed to be 80% to 90% effective in patients with factor VIII inhibitors due to the low cross-reactivity to pFVIII.8-11 Plasma-derived pFVIII is no longer available because of a contamination with parvovirus,12 but a recombinant pFVIII product is currently in clinical development.13 In patients with high-responding inhibitors (titer > 5 BU), acute bleeding is typically treated with an agent that bypasses the factor VIII or IX coagulation pathway, either activated prothrombin complex concentrates (aPCCs) or rFVIIa.2 In the United States, the only licensed aPCC is the plasma-derived factor VIII inhibitor bypassing activity, anti-inhibitor coagulant complex (FEIBA; Baxter AG, Vienna, Austria). Plasma-derived-aPCC (pd-aPCC) contains factor VII in mainly the activated form, as well as factor II, factor IX and factor X, in mainly non-activated forms.14 The precise mechanism by which pd-aPCC facilitates hemostasis is unknown, but prothrombin (factor II) and factor Xa are the primary active components, with other components including factor VIIa.14,15 A recent systematic review of available randomized clinical trial data showed that the pd-aPCC efficacy rate for controlling acute bleeding ranged from 64% to 80% of patients using dosing regimens according to published guidelines and manufacturer recommendations.16 Pd-aPCC is effective in controlling hemorrhage at a variety of anatomic sites including joint, muscle, mucocutaneous, and central nervous system (CNS) and perioperative bleeding.17-19 and can also be used effectively to achieve hemostasis in a home-treatment setting.14 Mild adverse events, such as chills, fever, nausea, and dizziness, occur in a small proportion of patients,20 and there is a small risk of anaphylactic reactions.21 Thrombotic and thromboembolic events (including disseminated intravascular coagulation [DIC], venous thrombosis, pulmonary embolism, myocardial infarction, and stroke) have been reported following infusion of pd-aPCC.21 Most of the thromboembolic events occurred when pd-aPCC was administered at doses higher than 200 units/kg/day and in patients with other risk factors for thromboembolic events.14,21,22 Patients receiving more than 100 units/kg of body weight of the concentrate must be monitored for the development of DIC and/or symptoms of acute coronary ischemia.21 In addition, the infusion time for this agent varies from about 30–45 minutes per infusion, to minimize side effects of rapid infusion. Since pd-aPCC is derived from human plasma, there is also the theoretical potential for human viral transmission, although no cases of hepatitis or human immunodeficiency virus infection have been directly linked to use of this agent.22,23 In addition, pd-aPCC contains trace amounts of factor VIII that may induce an anamnestic rise in factor VIII antibody titers in up to 30% of patients.19,21 This rise in antibody titers does not interfere with the efficacy of pd-aPCC and is transient in the majority of patients.20 Despite these limitations, this product has been widely used for about 30 years and continues to be used in patients who may not respond to rFVIIa.
Recombinant factor VIIa is the other currently available bypassing agent that was approved by the US Food and Drug Administration (FDA) in 1999 for use in patients with inhibitors. In contrast to pd-aPCC, rFVIIa is a recombinant protein produced by genetically engineered mammalian cells (baby hamster kidney cell line) and has little to no risk of human viral transmission. Furthermore, because it does not contain any residual procoagulant factor VIII or factor IX activity, the risk of an anamnestic response is precluded, and this agent can be used for patients with inhibitors to factor VIII or factor IX. In clinical studies, rFVIIa has been shown to be effective in restoring hemostasis in hemophilia A and hemophilia B patients with inhibitors who were experiencing joint, muscle, dental, and CNS bleeds, or who underwent major and minor surgeries. An estimate of rFVIIa efficacy for controlling bleeding derived from a recent systematic analysis of available randomized clinical trial data showed an effective treatment response rate of 81% to 91% in patients with inhibitors experiencing acute bleeds. The most commonly reported adverse events in clinical studies were mild and included fever, skin reactions, headache, hypertension, epistaxis, shortened prothrombin time, and reduced fibrinogen levels. The risk of thromboembolic events with rFVIIa is low and similar to that observed with pd-aPCC.

Although both types of bypassing agents can be administered at home, rFVIIa may be more suited to this use because it is a low-volume injection that can be administered rapidly. However, rFVIIa has to be administered frequently, every 2 to 3 hours because of its shorter half-life, whereas the recommended interval between doses of pd-aPCC is 6 to 12 hours. The FEIBA NovoSeven Comparative (FENOC) Study was a head-to-head comparison of efficacy between pd-aPCC and rFVIIa, and was conducted as a prospective, open-label, crossover, randomized equivalency-designed clinical trial in which a difference in response at 6 hours after treatment of no more than 15% was determined to be clinically equivalent. At 6 hours in the FENOC Study, the confidence interval reported for each product only slightly exceeded the 15% boundary (–11.4% to 15.7%, P = 0.059). The investigators, however, noted that their study was not designed nor adequately powered to provide evidence of the superiority of either product. They further suggested that an individualized approach to therapy should be used to optimize therapy, as there was evidence of substantial interpatient variability.

**Prophylaxis**

Because of the clear benefit of preventing hemarthroses for the preservation of joint integrity and maintenance of mobility and function, prophylaxis with factor VIII or IX is used routinely in many developed countries. Similarly, prophylaxis with bypassing agents is also being considered in inhibitor patients to minimize or prevent bleeding episodes. The prophylactic use of bypassing agents has been examined in a randomized clinical trial and several small series of patients with hemophilia A and inhibitors. In a recent trial, 22 patients with inhibitors to factor VIII were randomized to once-daily injections of rFVIIa 90 mcg/kg or 270 mcg/kg prophylaxis for 3 months. rFVIIa treatment reduced the number of bleeds (45%–59%; P < 0.0001 versus no prophylaxis) and reduced hospital admissions and work/school absences. Effects on bleeding frequency were largely maintained throughout a 3-month post-prophylaxis evaluation period. In many reports from case series, pd-aPCC and rFVIIa appeared to be effective and well tolerated as prophylactic therapy, with a reduced incidence of bleeding episodes, fewer workdays missed, improved quality of life, and less need for on-demand therapy, all variously reported. However, concerns have been raised about the risks (particularly of thromboembolism) with repeated and frequent use of pd-aPCC and the potential for anamnestic increases in antibody titers. Although the available data on prophylaxis are promising, much more research is required before the prophylactic use of bypassing agents becomes routine practice, in particular, in terms of defining the optimal regimen to use in this setting, the long-term risks and benefits, and the cost-utility of this approach.

**Limitations**

The availability of bypass agents has greatly advanced the treatment of hemophilia in patients with inhibitors; however, a few product-related practical limitations remain. Neither pd-aPCC nor the original formulation of rFVIIa are sufficiently stable at room temperature to be stored or transported without refrigeration. Thus, availability of product when away from home is dependent on an individual’s willingness to carry a cooler. Delays in treatment also arise from the need to restore these agents to room temperature prior to reconstitution.

**New advance in formulation: room temperature stable rFVIIa**

A room temperature stable formulation of rFVIIa (rFVIIa-RT; NovoSeven® RT; Novo Nordisk A/S, Bagsvaerd, Denmark) was approved by the FDA in May 2008. Studies have shown that this product can be stored at temperatures of 2°C to 25°C (36°F–77°F) for up to 2 years.
prior to reconstitution and for up to 3 hours following reconstitution.\textsuperscript{45} In addition, the concentration of this formulation was changed to make dosing calculations easier, and the vials are color coded to decrease confusion between the different vial sizes.

**Stability**

The stability of rFVIIa-RT, both in lyophilized and reconstituted forms, has been tested in a range of potential storage conditions.\textsuperscript{45} As reported in the study by Nedergaard et al, the specific activity of FVIIa in a 5 mg dose of rFVIIa-RT

![Graph A](image1.png)

**Figure 1 A)** Specific activity of the room temperature stable formulation of activated recombinant factor VII (rFVIIa-RT) during long-term storage at 5°C/41°F, 25°C/77°F, and 30°C/86°F, and during long-term storage at 40°C/104°F for 6 months followed by an additional 12 months at 25°C/77°F. Data for the 1 mg, 2 mg, and 5 mg product sizes were equivalent. Results from the 5 mg size are presented. **B)** Specific activity of rFVIIa-RT during storage at extreme temperatures for 12 hours. The broken lines represent the allowable upper and lower limit for each test parameter at the end of the product’s shelf-life, as adopted by the European Medicines Agency and the US Food and Drug Administration.\textsuperscript{45} This article was published in Clinical Therapeutics, Nedergaard et al.\textsuperscript{45} Copyright © 2008, Elsevier.
lyophilized product was maintained after 24 months of storage at 5°C (41°F) and 25°C (77°F), after 12 months and 18 months of storage at 30°C (86°F), and after 6 months at 40°C (104°F) followed by an additional 12 months at 25°C (77°F) (Figure 1A).

Moreover, rFVIIa-RT continued to maintain activity and was generally stable after 12 hours of storage at extreme temperatures (50°C [122°F], 60°C [140°F], and 70°C [158°F]) (Figure 1B), such as those that might be encountered during routine transport by patients. Stability and specific activity were also maintained when the rFVIIa-RT formulation was stored in the refrigerator (5°C [41°F]) and then at high room temperature (30°C [86°F]) for alternating periods over 5 days. Stability was independent of vial size.45

After reconstitution with histidine diluents, the rFVIIa-RT formulation retained its activity and stability when stored for 6 hours at 25°C (77°F) and for 24 hours at 5°C (41°F). Another study demonstrated that rFVIIa-RT remained physically and chemically stable at 25°C (77°F) for 6 hours after reconstitution with sterile water for injection, physiologic saline, or histidine diluent (Table 1).46 In this study, rFVIIa-RT was also shown to be stable at 5°C (41°F) for up to 24 hours when reconstituted with inappropriate diluents (sterile water for injection or physiologic saline) or the recommended histidine diluent. This is of interest to note in urgent or critical situations where only sterile saline or water for injection may be available for reconstitution. rFVIIa-RT stability is also maintained with various “incorrect” volumes of diluent.46 Reconstitution in double or half of the histidine solvent does not adversely affect stability; however, there is still a potential for dosing errors because the target final dose cannot be achieved if the correct diluent volume is not used.46

Table 1 In vitro stability of rFVIIa-RT after reconstitution with correct volumes of inappropriate solvents (sterile water for injection or saline) and the appropriate histidine diluent46

<table>
<thead>
<tr>
<th>Storage time (h)</th>
<th>Storage temperature (°C/°F)</th>
<th>Concentration (mg/mL)</th>
<th>Dimer/oligomer formation (%)</th>
<th>Polymer formation (%)</th>
<th>Heavy chain degradation (%)</th>
<th>Oxidized forms (%)</th>
<th>pH</th>
</tr>
</thead>
<tbody>
<tr>
<td>rFVIIa-RT</td>
<td>1 mg reconstituted with 1.15 mL recommended solvent (histidine)</td>
<td>0 – 6 25/77</td>
<td>0.97 0.99 0.96 0.95 0.97 0.98</td>
<td>1.4 1.3 1.5 1.3 1.5</td>
<td>&lt;0.3 &lt;0.3 &lt;0.3 &lt;0.3 &lt;0.3</td>
<td>8.5 8.6 8.8 8.7 8.7</td>
<td>1.2 1.2 1.2 1.2 1.2</td>
</tr>
<tr>
<td>rFVIIa-RT</td>
<td>1 mg reconstituted with 1.15 mL sterile water</td>
<td>0 6 25/77</td>
<td>0.97 0.96 0.97</td>
<td>1.5 1.5</td>
<td>&lt;0.3 &lt;0.3</td>
<td>8.7 8.7</td>
<td>1.2 1.2</td>
</tr>
<tr>
<td>rFVIIa-RT</td>
<td>1 mg reconstituted with 1.15 mL physiologic saline</td>
<td>0 6 25/77</td>
<td>0.97 0.98</td>
<td>1.5 1.5</td>
<td>&lt;0.3 &lt;0.3</td>
<td>8.6 8.6</td>
<td>1.2 1.2</td>
</tr>
</tbody>
</table>

Note: The limit of quantification of the analysis was 0.3%. This article was published in Clinical Therapeutics, Petersson et al.46 Copyright © 2008, Elsevier. Abbreviation: rFVIIa-RT, room temperature stable activated recombinant factor VII.

Stability at room temperature for this product was achieved through the addition of 2 new excipients to the lyophilized powder – a stabilizer (sucrose) and an antioxidant (methionine) – and by the use of a diluent containing histidine 10 mmol/L in sterile water. Histidine, a naturally occurring amino acid, is used as a buffering agent in other marketed factor replacement products and thus has a history of safe use in this patient population.45,46

Vial sizes

To aid in dose calculations at home, the concentration of rFVIIa-RT was changed to 1 mg/mL, and rFVIIa-RT is available in single-use vials containing 1 mg, 2 mg, or 5 mg of rFVIIa-RT per vial. This is in contrast to the original rFVIIa preparation, which was available in 1.2 mg, 2.4 mg, and 4.8 mg vial sizes. Because it is 40% more concentrated than the original rFVIIa formulation, the RT formulation allows for a lower infusion volume, and thus faster infusion than the original product.47 To make administration easier and avoid confusion, the vials of rFVIIa-RT and corresponding vials of premixed diluent now have matching color-coded caps to aid in differentiating between vials and to avoid medication errors.

Pharmacokinetic and pharmacodynamic equivalence

Pharmacokinetic and pharmacodynamic equivalence of rFVIIa-RT with original rFVIIa was demonstrated in a randomized, double-blind, 2-way crossover study in healthy volunteers.48 Factor VII activity over time was nearly identical with the 2 formulations (Figure 2A),48 and the 90% confidence intervals for difference in the primary end point of area under the curve was 0.93, well within the 0.8 to 1.25 definition of bioequivalence. Coagulation
Table 2 Pharmacokinetic parameters after administration of single 90 μg/kg doses of original rFVIIa or rFVIIa-RT in a randomized crossover study.

<table>
<thead>
<tr>
<th>Mean (SD) pharmacokinetic parameter</th>
<th>rFVIIa</th>
<th>RT (n = 22)</th>
</tr>
</thead>
<tbody>
<tr>
<td>AUC₀⁻₅₀ h/IU/mL</td>
<td>122.04 (18.03)</td>
<td>113.26 (17.36)⁺</td>
</tr>
<tr>
<td>Cₘₐₓ (IU/mL)</td>
<td>55.44 (7.89)</td>
<td>52.83 (7.31)</td>
</tr>
<tr>
<td>AUC₀⁻₃₀ h/IU/mL</td>
<td>122.05 (18.01)</td>
<td>113.26 (17.36)</td>
</tr>
<tr>
<td>t½ (h)</td>
<td>3.48 (0.27)</td>
<td>3.54 (0.28)</td>
</tr>
<tr>
<td>Mean residence time, h</td>
<td>2.97 (0.26)</td>
<td>3.05 (0.27)</td>
</tr>
<tr>
<td>CL, mL/h/kg</td>
<td>37.63 (5.99)</td>
<td>40.43 (6.23)</td>
</tr>
<tr>
<td>Vₐ, mL/kg</td>
<td>82.68 (12.50)</td>
<td>86.36 (12.31)</td>
</tr>
<tr>
<td>Vₚₚ, mL/kg</td>
<td>111.31 (17.52)</td>
<td>122.96 (20.42)</td>
</tr>
</tbody>
</table>

Notes: ⁺P = 0.1076 for RT vs original formulation.

Abbreviations: rFVIIa, activated recombinant factor VII; rFVIIa-RT, room temperature stable rFVIIa; SD, standard deviation; AUC, area under the curve; Cₘₐₓ, maximal concentration; t½, half-life; CL, clearance; Vₐ, volume of distribution in the central compartment; Vₚₚ, volume of distribution at steady state.

parameters, including levels of prothrombin fragment F₁⁺₂ (Figure 2B) and D dimer (Figure 2C), activated partial thromboplastin time at 30 minutes postdose, and prothrombin time at 5 hours and 24 hours postdose, were also similar with the 2 formulations. Mean pharmacokinetic profiles were similar for the 2 formulations and are summarized in Table 2. A comparable hemostasis profile was demonstrated by consistent measures of coagulation and fibrinolysis. No adverse events were reported with the RT formulation in this study. In addition, no subjects developed treatment-related factor VIIa antibodies during the course of the trial.

Conclusion

Despite remarkable advances in the treatment of hemophilia in recent decades, unmet clinical needs still exist, particularly for patients whose condition is complicated by the development of high-titer inhibitors. Although long-term eradication of inhibitors by immune tolerance is desirable, the mainstay of treatment is the use of bypassing agents to treat acute bleeding episodes. The development of the rFVIIa-RT formulation allows immediate access through an improvement in portability, ease of storage, and the time needed for reconstitution, and should be a benefit to patients with hemophilia and inhibitors and their providers.

Disclosure

Editorial support was provided by ETHOS Health Communications, through financial support from Novo Nordisk Inc, in compliance with international Good Publication Practice guidelines. Dr Mathew has received research and educational funding at The University of New Mexico from the following companies: Bayer HealthCare Pharmaceuticals, Baxter Healthcare Corporation, CSL Behring, Novo Nordisk Inc, and Wyeth Pharmaceuticals. Drs Butros and Boayue have nothing to disclose.
References


44. NovoSeven® RT [Coagulation Factor VIIa (Recombinant)] Room Temperature Stable [prescribing information]. Novo Nordisk, Princeton, NJ; August 2010.


